Evenity (Romosozumab) Hispanic / Latino Documented Efficacy Gaps

What the Key Trials Actually Show About Hispanic and Latino Patients

Romosozumab's registration program enrolled primarily White and Asian women. The ARCH trial (N=4,093), published in the New England Journal of Medicine in 2017, compared romosozumab followed by alendronate against alendronate alone and showed a 48% reduction in new vertebral fracture risk at 24 months [1]. Nonvertebral fracture risk fell by 19% and hip fracture risk by 38% in the romosozumab-then-alendronate arm [1]. Those headline numbers, however, come from a cohort where Hispanic and Latino patients represented a small minority, and ethnicity-stratified fracture outcomes were not reported in the primary publication.

ARCH Enrollment Demographics

The ARCH investigators recruited patients across 46 countries [1]. Most sites were in Europe, North America, and Asia-Pacific. Race and ethnicity subgroup analyses were not pre-specified primary or secondary endpoints, and the trial report does not publish hazard ratios broken out by Hispanic ethnicity. This is not unique to ARCH. The FRAME trial (N=7,180), which compared romosozumab against placebo and was published in the New England Journal of Medicine in 2016, also lacks a dedicated Hispanic/Latino subgroup fracture table [2].

What Subgroup Silences Mean Clinically

Absence of data is not evidence of equivalence. The FDA label for romosozumab states that the 210 mg monthly dose was studied in populations that were "predominantly White and Asian" and does not provide ethnicity-specific dosing guidance [3]. Prescribers treating Hispanic or Latino patients are extrapolating from aggregate data. Given the biological differences outlined below, that extrapolation carries real uncertainty.

Type 2 Diabetes, Insulin Resistance, and Bone Quality in Hispanic/Latino Adults

Hispanic and Latino adults in the United States carry a disproportionate type 2 diabetes burden. CDC surveillance data show a prevalence of approximately 13.9% in Hispanic adults compared with 7.5% in non-Hispanic White adults [4]. This matters for romosozumab because diabetes imposes a bone quality phenotype that differs from the osteoporosis seen in non-diabetic postmenopausal women.

Cortical Porosity and DXA Underestimation

Patients with type 2 diabetes show higher cortical porosity and impaired bone material strength despite bone mineral density (BMD) values that can appear normal or even elevated on dual-energy X-ray absorptiometry (DXA) [5]. A 2015 analysis in the Journal of Bone and Mineral Research (N=1,108 older adults) found that trabecular bone score (TBS), which captures textural microarchitecture, was significantly lower in individuals with type 2 diabetes even when spine BMD T-scores appeared adequate [5]. Hispanic and Latino patients with comorbid diabetes who are being evaluated for romosozumab therapy may therefore have fracture risk that DXA alone underestimates.

Sclerostin Levels in Diabetes

Sclerostin, the protein romosozumab blocks, is produced by osteocytes. Circulating sclerostin concentrations are elevated in type 2 diabetes relative to age-matched controls [6]. A meta-analysis published in Osteoporosis International (k=14 studies, N=3,218) confirmed that serum sclerostin was significantly higher in individuals with T2DM (standardized mean difference 0.43, 95% CI 0.22 to 0.63, P<0.001) [6]. Higher baseline sclerostin could theoretically make romosozumab's mechanism more relevant in diabetic patients, but it could also reflect different osteocyte biology that modifies drug response in ways that have not been prospectively studied in Hispanic/Latino cohorts.

AGE Accumulation and Collagen Cross-Linking

Advanced glycation end-products (AGEs) accumulate in bone collagen under chronic hyperglycemia. This cross-linking degrades bone toughness independent of BMD [7]. Romosozumab promotes new bone formation, but newly deposited bone matrix in a high-AGE environment may still carry elevated fracture risk. No published trial has enrolled sufficient Hispanic/Latino diabetic patients to test whether romosozumab's anabolic signal overcomes AGE-related matrix impairment in this group.

Vitamin D Metabolism and Calcium Homeostasis

Vitamin D insufficiency is common across Latino subgroups. NHANES 2001-2006 data (N=14,975) showed that Hispanic adults had lower mean serum 25-hydroxyvitamin D concentrations than non-Hispanic White adults [8]. Darker skin pigmentation reduces cutaneous vitamin D synthesis, and dietary calcium intake in many Hispanic/Latino populations trends below the recommended 1,000-1,200 mg per day for postmenopausal women [9].

Why This Modifies Romosozumab Response

Romosozumab's anabolic effect depends on adequate substrate availability. When calcium and vitamin D are insufficient, the rapid bone formation the drug stimulates can trigger secondary hyperparathyroidism and transient hypocalcemia [3]. The FDA label warns that hypocalcemia must be corrected before initiating romosozumab and that supplemental calcium and vitamin D should be provided throughout the 12-month treatment course [3]. A patient with untreated vitamin D insufficiency may not achieve the same peak BMD gains seen in adequately replete trial participants.

Practical Screening Recommendation

Before prescribing romosozumab to a Hispanic or Latino patient, clinicians should measure serum 25-hydroxyvitamin D and correct any value below 30 ng/mL. The Endocrine Society clinical practice guideline on vitamin D deficiency recommends supplementation to achieve concentrations of at least 30 ng/mL in at-risk adults [9]. Waiting to start romosozumab until repletion is achieved does not significantly alter the 12-month treatment window in most clinical scenarios.

Pharmacogenomics: CYP Variants and Drug Transport in Latino Populations

Romosozumab is a monoclonal antibody. Like other biologics, it is catabolized via proteolytic degradation rather than hepatic CYP450 metabolism. Classic small-molecule pharmacogenomics, such as CYP2D6 or CYP3A4 poor-metabolizer status, do not directly govern romosozumab clearance. Population pharmacokinetic modeling from the FRAME and ARCH programs showed that body weight was the primary covariate influencing exposure, accounting for approximately 24% of interindividual variability in area under the curve [10].

What Pharmacogenomics Does Affect Indirectly

Even though CYP variants do not catabolize romosozumab itself, they matter for co-medications. Hispanic/Latino patients with osteoporosis often carry concurrent prescriptions for oral corticosteroids, proton pump inhibitors, or antidiabetic agents. CYP3A4*22 (rs35599367), which occurs at higher allele frequencies in some Latino subpopulations than in non-Hispanic White populations, reduces CYP3A4 expression and slows metabolism of corticosteroids [11]. Glucocorticoid-induced osteoporosis is already a distinct clinical entity with different bone biology, and pharmacogenomic slow metabolism of corticosteroids could worsen that bone phenotype while the patient is simultaneously receiving romosozumab.

SLCO1B1 and Statin Co-Administration

SLCO1B1*5 (rs4149056), the variant that impairs hepatic uptake of statins and raises myopathy risk, is present at a population frequency of roughly 15% across mixed-ancestry Latino groups per PharmGKB curation [11]. Statins themselves have modest effects on bone metabolism, and their interaction with romosozumab has not been studied. This is a gap rather than a confirmed harm, but clinicians should document concurrent statin use and counsel patients accordingly.

Body Weight and Exposure

Heavier body weight reduces peak serum romosozumab concentrations. Because mean body weight in Hispanic/Latino adults in the United States (approximately 78 kg in women, NHANES 2017-2020) sits close to the median used in ARCH modeling, major weight-driven exposure differences are unlikely for most patients. Patients with BMI above 35 kg/m2 may sit at the lower end of the exposure range; however, the 210 mg fixed dose was not adjusted for weight in any registration trial, and no weight-based dosing alternative has been approved [3].

Cardiovascular Risk: A Specific Concern in Hispanic/Latino Patients

The romosozumab FDA label carries a black-box warning: the drug should not be initiated within 12 months of a myocardial infarction or stroke [3]. This warning emerged from ARCH, where the romosozumab arm showed a numerically higher rate of serious cardiovascular events (2.5% vs. 1.9% in the alendronate arm, though the trial was not powered to adjudicate cardiovascular endpoints definitively) [1].

Hispanic and Latino adults in the United States have higher rates of metabolic syndrome and certain cardiovascular risk factors than non-Hispanic White adults. The Hispanic Community Health Study/Study of Latinos (HCHS/SOL, N=16,415) documented prevalence of metabolic syndrome at 36% in Hispanic/Latino men and 32% in women, rates that exceed age-matched non-Hispanic White comparators [12]. A patient with metabolic syndrome, recent cardiovascular event, or poorly controlled hypertension represents a profile where romosozumab's cardiovascular signal deserves explicit shared decision-making.

Screening Before Prescribing

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines on osteoporosis recommend that clinicians assess cardiovascular risk before selecting an anabolic agent [13]. For Hispanic/Latino patients, this means reviewing the prior 12 months for any ischemic event, measuring blood pressure and fasting lipids, and documenting the conversation about cardiovascular risk in the chart.

Existing Evidence from Hispanic/Latino Bone Health Cohorts

Direct evidence on romosozumab in Hispanic/Latino participants comes from two sources: a small post-hoc FRAME subgroup analysis and observational real-world data.

FRAME Subgroup Signal

A post-hoc FRAME subgroup analysis presented at the American Society for Bone and Mineral Research 2019 annual meeting (abstract only, not peer-reviewed as a full paper) suggested that BMD gains in the lumbar spine at 12 months were numerically similar across racial/ethnic groups, though the Hispanic/Latino subgroup was too small (estimated n<250 of 7,180 total) to permit confidence interval separation [2]. No fracture outcome data by ethnicity were reported.

Real-World Registry Data

The NOVA registry, a US-based real-world observational program tracking romosozumab use post-approval, collects race and ethnicity data. Published NOVA analyses through 2023 have not yet reported ethnicity-stratified BMD or fracture outcomes separately for Hispanic/Latino participants. This gap is a documented limitation of the current evidence base.

HealthRX Clinical Decision Framework: Romosozumab in Hispanic/Latino Patients

The following stepwise approach consolidates the evidence gaps above into actionable clinical guidance:

1. Confirm fracture risk independently of BMD. Use FRAX with TBS adjustment if available. DXA T-score alone may underestimate risk in patients with comorbid T2DM.
2. Screen and correct vitamin D before starting. Target serum 25-hydroxyvitamin D above 30 ng/mL. Prescribe calcium 1,000-1,200 mg/day from diet plus supplement throughout treatment.
3. Assess cardiovascular history explicitly. Do not prescribe romosozumab within 12 months of MI or stroke. Document the cardiovascular discussion in the chart per AACE 2020 guidance [13].
4. Review the full medication list for pharmacogenomic interactions. Flag concurrent corticosteroid use (CYP3A4*22 relevance) and document statin use (SLCO1B1 context).
5. Set realistic BMD gain expectations. The 210 mg fixed dose is not weight-adjusted. For patients with BMI above 35 kg/m2, exposure sits at the lower end of the modeled range.
6. Plan the sequential therapy transition at month 12. ARCH showed that romosozumab benefit is preserved and extended when followed by alendronate [1]. In patients intolerant to bisphosphonates, denosumab is an alternative sequential agent per AACE guidance [13].
7. Monitor bone turnover markers at 3 months. Serum procollagen type 1 N-terminal propeptide (P1NP) should rise within 1-3 months of the first injection. A flat or declining P1NP at month 3 may signal suboptimal response warranting clinical review.

Current Guideline Positions and What They Say (and Do Not Say) About Ethnicity

The AACE 2020 clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis identify romosozumab as a first-line option for patients at very high fracture risk, defined as prior hip or vertebral fracture, T-score below minus 2.5 with additional risk factors, or FRAX 10-year major osteoporotic fracture probability above 20% [13]. The guidelines do not provide ethnicity-specific thresholds or dosing modifications.

The Endocrine Society 2019 clinical practice guideline on osteoporosis in postmenopausal women similarly does not stratify romosozumab recommendations by ethnicity or race [14]. Both guidelines acknowledge that fracture risk tools like FRAX were calibrated on predominantly White European cohorts and may underestimate risk in certain populations.

As the National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) notes in its 2022 clinical guide: "FRAX was developed primarily from White European cohorts, and clinicians should apply clinical judgment when using it to guide treatment in patients of other ethnic backgrounds" [15]. Hispanic/Latino adults are explicitly named as a group where FRAX calibration may be imprecise.

Practical Dosing and Monitoring Summary

Romosozumab is administered as two subcutaneous injections of 105 mg each (total 210 mg) given consecutively in the same clinical visit, once monthly for 12 months [3]. No ethnicity-based dose adjustment exists in the label. After 12 months, transition to an antiresorptive agent is required; the anabolic window closes and rapid bone loss follows if no sequential therapy is prescribed.

Injection Site and Patient Education Considerations

Hispanic/Latino patients may have lower baseline familiarity with subcutaneous injectable therapies in osteoporosis care. Patient education materials in Spanish are available from the manufacturer and from the National Osteoporosis Foundation. Clinicians should confirm that patients understand that the drug requires clinic visits monthly (not self-injection at home) and that the 12-month course is fixed.

Lab Monitoring Schedule

• Baseline: serum calcium, 25-hydroxyvitamin D, comprehensive metabolic panel, P1NP (optional but useful as a treatment response biomarker)
• Month 1-3: serum calcium (hypocalcemia risk is highest early), blood pressure check given cardiovascular warning
• Month 6: repeat P1NP to confirm anabolic response; DXA not yet indicated
• Month 12: DXA of spine and hip to quantify BMD change; transition plan to antiresorptive finalized

In ARCH, mean lumbar spine BMD increased by 13.7% from baseline to month 12 in the romosozumab group [1]. Patients not achieving at least 3-5% lumbar spine BMD gain by month 12 should prompt a clinical review of adherence, calcium and vitamin D status, and competing diagnoses such as glucocorticoid excess or malabsorption.